ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Abstract Number: 0429

Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Rheumatoid Arthritis: Results from a Randomized Phase 3 Study
Abstract Number: 0430

A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis
Abstract Number: 0431

Senescence and Cell Exhaustion in CD4+ and CD8+ Lymphocytes in Rheumatoid Arthritis Patients in Remission Without Treatment
Abstract Number: 0432

Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice
Abstract Number: 0433

DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis
Abstract Number: 0434

Effects of B/tsDMARDs on Non-inflammatory Pain in Patients with Rheumatoid Arthritis -ANSWER Longitudinal Cohort Study-
Abstract Number: 0435

Changes in Characteristics of Patients Initiating and Discontinuing Advanced Therapies for Rheumatoid Arthritis Following Release of Safety Data
Abstract Number: 0436

Patients with Difficult-to-treat Rheumatoid Arthritis Have Higher Levels of Inflammation on Ultrasound
Abstract Number: 0437

Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cardiovascular Outcomes in Rheumatoid Arthritis
Abstract Number: 0438

Association Between Methotrexate Use and Lymphoma in Rheumatoid Arthritis: A Systematic Literature Review
Abstract Number: 0439

Humoral Immune Response to 13 Valent-conjugate and 23-valent Polysaccharide Pneumococcal Vaccines in RA Patients Treated with Abatacept: Results of the Open Randomized Controlled Trial VACINA (Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients)
Abstract Number: 0440

Baseline T Cell and B Cell-related Markers and HLA-DRB1 Shared Epitope Alleles Predict the Therapeutic Efficacy of Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 0441

Outcomes in Patients with Rheumatoid Arthritis Initiating Therapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Abstract Number: 0442

Infliximab Clearance a Predictive Factor of Pharmacokinetic Origin in Relation to Suboptimal Pharmacokinetics and Immunogenicity in United States Based Rheumatology Practices
Abstract Number: 0443

The Potential of an Oral TNFα Inhibitor with TNFR1 Specificity: Results of a Phase 1b Proof-of-mechanism Trial in Psoriasis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].